FDA Launches One-Day Inspectional Assessments to Expand Regulatory Oversight

FDA Introduces One-Day Inspectional Assessments

The U.S. Food and Drug Administration has announced a new initiative called One-Day Inspectional Assessments, designed to expand oversight activities and improve the agency’s ability to evaluate regulated facilities more efficiently.

According to FDA, the program is intended to complement existing inspection activities by allowing investigators to conduct shorter, targeted assessments focused on specific operational or compliance areas.

Purpose of the Initiative

FDA stated that One-Day Inspectional Assessments are intended to:

• Increase oversight coverage across regulated industries
• Improve operational efficiency for both FDA and industry
• Focus on specific compliance areas or targeted concerns
• Support risk-based inspectional approaches

The agency indicated these assessments may be used in situations where a full inspection may not be necessary to evaluate a particular issue or operation.

How These Assessments May Differ from Traditional Inspections

Unlike broader multi-day inspections, One-Day Inspectional Assessments are expected to be narrower in scope and more targeted toward specific objectives.

FDA noted that the assessments are designed to provide flexibility while still supporting regulatory oversight and compliance monitoring.

Potential Industry Impact

Companies subject to FDA oversight may wish to consider how shorter, targeted inspections could affect:

• Inspection readiness programs
• Documentation accessibility and organization
• Personnel availability during inspections
• Internal response procedures for focused assessments

Although limited in duration, these assessments may still evaluate critical compliance areas and require timely access to records and personnel.

EAS Perspective

The initiative reflects FDA’s continued focus on modernizing inspectional approaches and expanding oversight capabilities through more flexible, risk-based strategies.

Companies should ensure inspection readiness programs remain effective for both comprehensive inspections and shorter targeted assessments.

EAS will continue monitoring FDA inspection and compliance initiatives and provide updates as additional details become available.